BioXcel Therapeutics
BTAI
96 hedge funds and large institutions have $325M invested in BioXcel Therapeutics in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 10 closing their positions.
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
58% more call options, than puts
Call options by funds: $5.79M | Put options by funds: $3.67M
16% more funds holding
Funds holding: 83 → 96 (+13)
13% more capital invested
Capital invested by funds: $287M → $325M (+$37.6M)
11% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 27
0.75% more ownership
Funds ownership: 3% → 3.75% (+0.75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$37.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$35.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$32.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$5.99M |
| 5 |
Two Sigma Investments
New York
|
+$5.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$9.4M |
| 2 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$6.49M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.82M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.13M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.12M |
BTAI Hedge Fund Activity: Q1 2023 in Review
96 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2023, worth a combined $325M — up 13% from $287M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BTAI positions and 10 closed out — a net gain of 13 holders — while 30 added to existing stakes and 27 trimmed.
The largest buyer was State Street, adding an estimated $37.2M. The largest seller was Artemis Investment Management, cutting an estimated $9.4M.
- 96 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2023, up from 83 in Q4 2022.
- Funds reported $325M of BioXcel Therapeutics stock for Q1 2023, up 13% quarter-over-quarter.
- 23 funds opened new BioXcel Therapeutics positions in Q1 2023 and 10 closed out, a net change of +13 holders.
- The largest BioXcel Therapeutics buyer in Q1 2023 was State Street, an estimated $37.2M added.
- The largest BioXcel Therapeutics seller in Q1 2023 was Artemis Investment Management, an estimated $9.4M sold.
Based on aggregated 13F filings for Q1 2023.